Elscint's major investment in MRI has apparently begun to payoff. The Haifa, Israel, company this month reported that a 120%increase in MRI sales contributed to strong revenue growth in1996, although the vendor is experiencing profitability problemsthat
Elscint's major investment in MRI has apparently begun to payoff. The Haifa, Israel, company this month reported that a 120%increase in MRI sales contributed to strong revenue growth in1996, although the vendor is experiencing profitability problemsthat have required some cost-reduction measures.
For the year (end-December), Elscint reported revenues of $311.4million, up 10% compared with $281.9 million in 1995. The companyhad net income last year of $8.1 million, compared with $14.5million the year before.
In the past several years, Elscint has broadened its once-thinMRI product line and now offers scanners at five different fieldstrengths. Its most recent new magnet introduction was the 1-teslaPrima 1TG, which debuted at last year's Radiological Society ofNorth America meeting (SCAN 12/4/96).
In addition to its growth in MRI revenues, Elscint said that systemssales in the U.S. increased 25%, mostly due to the success ofits CT Twin Flash scanner, which gained market share in the modality.Fourth-quarter sales in Elscint's nuclear medicine division alsogrew, due to shipments of its VariCam variable-angle, dual-headcamera.
Despite the revenue growth, Elscint president and CEO JonathanAdereth said that the company was disappointed with its levelsof profitability. To cut costs, Elscint has reduced personnel,reorganized some of its regional operations, and instituted asalary freeze. Along with an effort to reduce manufacturing costs,the moves should improve operating profit through 1997, Aderethsaid.
New Literature Review Assesses Merits of Cardiac MRI After Survival of Sudden Cardiac Arrest
April 19th 2024While noting inconsistencies with the diagnostic yield of cardiac MRI in patients who survived sudden cardiac arrest, researchers cited unique advantages in characterizing ischemic cardiomyopathy (ICM) and facilitating alternate diagnoses.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.